Back to Journals » Breast Cancer: Targets and Therapy » Volume 6

The role of peroxiredoxin II in chemoresistance of breast cancer cells

Authors Wang T, Diaz AJ, Yen Y

Received 24 January 2014

Accepted for publication 27 March 2014

Published 23 May 2014 Volume 2014:6 Pages 73—80


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Tieli Wang,1 Anthony Joseph Gomez Diaz,1 Yun Yen2

1Department of Chemistry and Biochemistry, California State University Dominguez Hills, Carson, CA, USA; 2Department of Clinical and Molecular Pharmacology, Beckman Research Institute of City of Hope National Medical Center, Duarte, CA, USA

Abstract: Peroxiredoxin (Prx)II belongs to a family of redox-active proteins that use redox-sensitive cysteine in the active site to reduce peroxides. PrxII is induced by various oxidative stimuli and plays an important protective role against oxidative radical damage by reactive oxygen species. PrxII expression levels are correlated with resistance to radiation therapy or certain anti-cancer drugs in radioresistant breast cancer cells, glioblastomas, and head and neck cancer cells as well as in tissue isolated from head and neck patients who do not respond to radiation therapy. Small interfering RNA (siRNA) that inhibits the PrxII gene expression has been shown to partially reverse the radioresistant phenotype in radiation resistant breast cancer cells and sensitizes glioma cells to oxidative stress, highlighting the potential clinical importance of PrxII in radiation resistance in cancer. This article focuses on the role that PrxII may play in chemoresistant breast cancer cells.

Keywords: siRNA, redox, cysteine disulfide bridges, targeted therapy, reactive oxygen species

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]